HOOKIPA PharmaHOOK
About: HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Employees: 124
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.31% more ownership
Funds ownership: 36.75% [Q2] → 37.06% (+0.31%) [Q3]
4% less capital invested
Capital invested by funds: $21M [Q2] → $20.2M (-$780K) [Q3]
15% less funds holding
Funds holding: 41 [Q2] → 35 (-6) [Q3]
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
82% less call options, than puts
Call options by funds: $155K | Put options by funds: $868K
91% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 23
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
RBC Capital Brian Abrahams 22% 1-year accuracy 15 / 68 met price target | 1,652%upside $48 | Outperform Maintained | 15 Nov 2024 |
Financial journalist opinion
Based on 3 articles about HOOK published over the past 30 days
